期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 28, 期 22, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2020.115734
关键词
Gamma secretase modulator; Alzheimer's disease; Amyloid beta; A beta 42 reduction; Structure activity relationship; Methoxypyridines
资金
- SRI International
- Cure Alzheimer's Fund (CAF)
- NIH
- NIA
- NINDS through a Blueprint Neurotherapeutics Award [U01 NS074501]
The evolution of gamma-secretase modulators (GSMs) through the introduction of novel heterocycles with the goal of aligning activity for reducing the levels of A beta 42 and properties consistent with a drug-like molecule are described. The insertion of a methoxypyridine motif within the tetracyclic scaffold provided compounds with improved activity for arresting A beta 42 production as well as improved properties, including solubility. In vivo pharmacokinetic analysis demonstrated that several compounds within the novel series were capable of crossing the BBB and accessing the therapeutic target. Treatment with methoxypyridine-derived compound 64 reduced A beta 42 levels in the plasma of J20 mice, in addition to reducing A beta 42 levels in the plasma and brain of Tg2576 mice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据